References
- Hogan LE, Meyer JA, Yang J, et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 2011; 118: 5218–5226.
- Bhatla T, Wang J, Morrison DJ, et al. Epigenetic reprogramming reverses the relapse- specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 2012;119: 5201–5210.
- Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157–163.
- Knoechel B, Roderick JE, Williamson KE, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Gene 2014; 46: 364–370.
- Burke MJ, Lamba JK, Pounds S, et al. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol 2014; 89: 889–895.
- Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigene 2013; 5: 3.
- Maude SL, Dolai S, Delgado-Martin C, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood 2015; 125: 1759–1767.
- Masiero M, Minuzzo S, Pusceddu I, et al. Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells. Leukemia 2011; 25: 588–598.
- Chou T-CC. Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Res 2010; 70: 440–446.
- Morrison DJ, Hogan LE, Condos G, et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia 2012; 26: 271–279.
- Peirs S, Matthijssens F, Goossens S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 2014; 124: 3738–3747.
- Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147–156.
- Patrick K, Wade R, Goulden N, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contem-porary protocol, UKALL 2003. Br J Haematol 2014; 166: 421–424.
- McCormack MP, Shields BJ, Jackson JT, et al. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL. Blood 2013; 122: 2093–2103.
- Treanor LM, Zhou S, Janke L, et al. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med 2014; 211: 701–713.
- Zohren F, Souroullas GP, Luo M, et al. The transcription factor Lyl-1 regulates lymphoid specification and the maintenance of early T lineage progenitors. Nat Immunol 2012; 13: 761–769.
- Nagel S, Venturini L, Meyer C, et al. Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines. Leuk Res 2010; 34: 521–528.